3.73  -0.09 (-2.36%)		07-13 16:00
Open: 3.75 High: 3.84 Volume: 229,924		Pre. Close: 3.82 Low: 3.73 Market Cap: 36(M)

Short term
Mid term
Targets	6-month :	4.48	1-year :	4.89
Resists	First :	3.84	Second :	4.19
Pivot price	3.86
Supports	First :	3.27	Second :	2.72
MAs	MA(5) :	3.83	MA(20) :	3.83
	MA(100) :	3.79	MA(250) :	3.35
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	53	D(3) :	55.8
RSI	RSI(14): 47.8
52-week	High :	6.59	Low :	1.85

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SABS ] has closed below the lower bollinger band by 5.6%. Bollinger Bands are 65.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.85 - 3.87	3.87 - 3.89
Low:	3.67 - 3.69	3.69 - 3.72
Close:	3.68 - 3.73	3.73 - 3.77

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Tue, 07 Jul 2026
Breakthrough T1D Awards Grant to Support PRISE?hATG Study of SAB?142 in Stage 3 Type 1 Diabetes - Investing News Network

Tue, 07 Jul 2026
Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan

Sun, 05 Jul 2026
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance

Tue, 30 Jun 2026
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance

Fri, 26 Jun 2026
SABS Forecast — Price Target — Prediction for 2027 - TradingView

Fri, 26 Jun 2026
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	76 (M)
Shares Float	41 (M)
Held by Insiders	0.8 (%)
Held by Institutions	92 (%)
Shares Short	3,770 (K)
Shares Short P.Month	2,640 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-25.4 %
Return on Equity (ttm)	-0.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.52
Sales Per Share	0
EBITDA (p.s.)	-0.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	-51 (M)
Levered Free Cash Flow	-27 (M)

PE Ratio	-6.67
PEG Ratio	0
Price to Book value	1.24
Price to Sales	0
Price to Cash Flow	-5.57

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.